EVEREST MED (01952.HK): Two Products Enter 2026 National Reimbursement List

On 16 Nov 2026, EVEREST MED (01952.HK) said etrasimod and eravacycline joined China's 2026 reimbursement list from 1 January 2027.

NewTimeSpace News: On 16 November 2026, Everest Medicines Limited (stock code: 1952) published a voluntary announcement that etrasimod arginine tablets and eravacycline hydrochloride for injection have been added to the 2026 edition of the National Reimbursement Drug List for the first time through national price negotiations, effective 1 January 2027. Budesonide enteric-coated capsules remain on the list.

Etrasimod is described as China's first and only sphingosine-1-phosphate receptor modulator approved for ulcerative colitis as at November 2026, taken once daily. The National Medical Products Administration approved it in February 2026 for adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or are intolerant to conventional therapy or biologics. In the Asian multicentre Phase III ENLIGHT UC study, 12 weeks of induction plus 40 weeks of maintenance produced a clinical remission rate of 48.1%, mucosal healing of 51.9% and endoscopic normalisation of 45.5%.

Eravacycline is described as the world's first and only fully synthetic fluorocycline antibiotic as at November 2026, for complicated intra-abdominal infections in adults, with broad activity against multidrug-resistant gram-negative and gram-positive bacteria, anaerobes and atypical pathogens. It was approved by the NMPA in March 2023 and launched in mainland China in July 2023.

The reimbursement listing should further improve access to and affordability of both products, the Company said.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.